Will R&D Suffer When Pfizer, Allergan Merge?
This article was originally published in Scrip
Reducing Pfizer Inc.'s tax rate is undeniably the top reason for the company's pending $160bn merger with Allergan PLC, but without pharmaceutical products and research programs that could significantly boost revenue growth, it seems unlikely that Pfizer would invest billions of dollars and invoke the ire of US politicians and regulators by completing a tax inversion.
You may also be interested in...
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.
Nuvation started in 2018 and raised a $275m series A round in 2019. Now it is merging with the EcoR1 Capital-sponsored SPAC Panacea Acquisition Corp. and raising $500m in equity capital.
Public Company Edition: Codiak, Kiromic, Aligos and Opthea have fallen below their initial public offering values, while Tarsus and Praxis are trading higher. Also, 5AM, MPM and Cormorant took biotech SPACs public and Evotec led recent non-IPO financings with a €250m private placement.